Necitumumab plus Gemcitabine and Cisplatin as First-Line Therapy in Patients with Stage IV EGFR- Expressing Squamous Non-Small-Cell Lung Cancer: German Subgroup Data from an Open-Label, Randomized Controlled Phase 3 Study (SQUIRE) | Zendy

Martin Reck | Zendy; Michael Thomas | Zendy; Cornelia Kropf-Sanchen | Zendy; J. Mezger | Zendy; Mark A. Socinski | Zendy; H. Depenbrock | Zendy; Victoria Soldatenkova | Zendy; Jacqueline Brown | Zendy; Thomas Krause | Zendy; Nick Thatcher | Zendy

Open Access

Necitumumab plus Gemcitabine and Cisplatin as First-Line Therapy in Patients with Stage IV EGFR- Expressing Squamous Non-Small-Cell Lung Cancer: German Subgroup Data from an Open-Label, Randomized Controlled Phase 3 Study (SQUIRE)

Author(s) -

Martin Reck,

Michael Thomas,

Cornelia Kropf-Sanchen,

J. Mezger,

Mark A. Socinski,

H. Depenbrock,

Victoria Soldatenkova,

Jacqueline Brown,

Thomas Krause,

Nick Thatcher

Publication year - 2016

Publication title -

oncology research and treatment

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.553

H-Index - 48

eISSN - 2296-5262

pISSN - 2296-5270

DOI - 10.1159/000448085

Subject(s) - medicine , hazard ratio , lung cancer , gemcitabine , gastroenterology , oncology , cancer , confidence interval

In the SQUIRE study, adding the anti-epidermal growth factor receptor (EGFR) IgG1 antibody necitumumab to first-line gemcitabine and cisplatin (GC + N) in advanced squamous non-small-cell lung cancer (sqNSCLC) significantly improved overall survival (OS); the safety profile was acceptable. We explored data for the German subpopulation (N = 96) of SQUIRE patients with EGFR-expressing tumors.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research